Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Medical Specialties
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| TMO | Thermo Fisher Scientific, Inc. | 0.81% | 555.20 | 1.0% | $930.64m | |
| DHR | Danaher Corp. | 1.08% | 252.00 | 0.7% | $749.07m | |
| ABT | Abbott Laboratories | 0.77% | 113.30 | 0.8% | $675.41m | |
| ISRG | Intuitive Surgical, Inc. | 0.43% | 219.07 | 0.8% | $581.63m | |
| MDT | Medtronic Plc | -0.13% | 102.62 | 0.6% | $494.20m | |
| BSX | Boston Scientific Corp. | -0.73% | 39.20 | 1.0% | $401.20m | |
| SYK | Stryker Corp. | 0.74% | 232.22 | 1.3% | $381.48m | |
| ALGN | Align Technology, Inc. | 0.42% | 275.04 | 6.4% | $379.58m | |
| IDXX | IDEXX Laboratories, Inc. | 2.03% | 372.23 | 3.8% | $346.32m | |
| BDX | Becton, Dickinson & Co. | 0.48% | 252.34 | 1.0% | $322.56m | |
| EW | Edwards Lifesciences Corp. | 0.00% | 94.37 | 0.4% | $306.88m | |
| DXCM | DexCom, Inc. | 1.62% | 321.23 | 7.7% | $283.84m | |
| A | Agilent Technologies, Inc. | 2.28% | 125.20 | 1.6% | $264.01m | |
| BAX | Baxter International, Inc. | 0.90% | 73.25 | 1.8% | $242.11m | |
| MTD | Mettler-Toledo International, Inc. | 1.55% | 1238.58 | 5.8% | $192.31m |
Company Profile
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment consists of technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979, and is headquartered in Marlborough, MA.